Drug responses of AscleStem<sup>®</sup> Cardiomyocytes derived from nomal human iPS cells differentiated by 3D embryoid body formation protocol
-
- MORIMOTO Nobuhiro
- Nacalai Tesque, Inc.
-
- YOSHIMOCHI Kenji
- Nacalai Tesque, Inc.
-
- HASHIDA Koji
- Nacalai Tesque, Inc.
-
- OKAZAKI Yugo
- Nacalai Tesque, Inc.
-
- SHIMOTSUMA Motoshi
- Nacalai Tesque, Inc.
Bibliographic Information
- Other Title
-
- 健常ヒトiPS細胞由来心筋細胞 AscleStem<sup>®</sup> Cardiomyocytesの薬剤応答性の評価
Description
<p>Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been expected to provide new tools for regenerative medicine, drug discovery and safety assessment. Currently, some manufacturers supply their hiPSC-CMs, each of which is differentiated and purified in its own way from each iPS cells, therefore these cardiomyocytes show different characteristics from each other against drugs. Thus, it is necessary that a hiPSC-CM is characterized before assessment.</p><p>We have been offering "AscleStem® Cardiomyocytes" which are derived from human iPS cells differentiated with chemical compounds instead of cytokines by 3D embryoid body formation protocol, and purified with no antibiotics. In this study, we introduce "AscleStem® Cardiomyocytes" with drug-responses.</p>
Journal
-
- Annual Meeting of the Japanese Society of Toxicology
-
Annual Meeting of the Japanese Society of Toxicology 47.1 (0), P-156-, 2020
The Japanese Society of Toxicology
- Tweet
Details 詳細情報について
-
- CRID
- 1390567172568225920
-
- NII Article ID
- 130007898280
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed